<DOC>
	<DOCNO>NCT00519558</DOCNO>
	<brief_summary>This trial conduct Japan . The aim trial demonstrate superiority effect NN-220 compare placebo assess change percent truncal fat ( kg ) baseline 24 week ' treatment ( end treatment ) patient Growth Hormone Deficiency Adults ( GHDA ) .</brief_summary>
	<brief_title>Growth Hormone Deficiency Adults ( GHDA )</brief_title>
	<detailed_description />
	<mesh_term>Endocrine System Diseases</mesh_term>
	<mesh_term>Dwarfism , Pituitary</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<criteria>Subjects diagnose GHD If subject history treatment treatment tumour pituitary peripheral site , two year must pass since completion surgery , radiotherapy treatment , recurrence underlying disease exclude Appropriate replacement therapy administer 24 week treatment pituitary hormone deficiency Subject history acromegaly Subject diabetes mellitus Subject suffering malignancy Several medical condition</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>